Navigation Links
Isis Pharmaceuticals to Present at the 2009 Canaccord Adams Cardiovascular Conference
Date:11/3/2009

CARLSBAD, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Canaccord Adams' 2009 Cardiovascular Conference on Tuesday, November 10, 2009, at 11:00 a.m. PT at the Nikko Hotel in San Francisco.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

SOURCE Isis Pharmaceuticals, Inc.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
2. Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
3. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
4. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
5. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
6. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
7. Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full-Year Financial Guidance
8. Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics
9. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
10. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... ALTO, Calif. , June 9, 2017 ... device company focused on the design, manufacture, sale and ... the market on the progress of its commercial roll-out ... is now available in more than one hundred (100) ... AeroForm offers a needle-free alternative for ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
Breaking Medicine Technology:
(Date:6/24/2017)... Tampa, Fla. (PRWEB) , ... June 24, 2017 ... ... Fla., is now offering genetic testing for medications in select Florida and Texas ... of pharmacogenomics. , This new application of genetic testing recognizes the role ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island ... Care Management Alerts and Dashboards, an innovative new service enabling healthcare providers to ... Care Management Alerts and Dashboards provide near real-time data about patients admitted to ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Military Officers Association of America (MOAA) announced ... Veterans Affairs, retired Marine Col. Thomas G. Bowman. , Bowman currently serves as the ... an intimacy with the issues and challenges veterans face with the VA. Following a ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... The Aesthetic ... facelift . Dr. Talei has come up with a proprietary technique that he calls ... lifts tissues that have dropped. For all ages, patients can expect to look refreshed, ...
(Date:6/23/2017)... Santa Monica, CA (PRWEB) , ... June 23, 2017 , ... ... PureLife as the endorsed amalgam separator supplier for CDA members. As part of the ... a reduced price of $99, saving more than $400 off the retail value. This ...
Breaking Medicine News(10 mins):